文献速递免疫规划卫生政策与健康促进

单剂次疫苗程序真实世界影响研究的设计选项

Options for design of real-world impact studies of single-dose vaccine schedules.
PubMed 文献 · Vaccine · 2018-03-21

本文讨论在WHO政策决定前,部分国家可能试点或推广单剂次人乳头瘤病毒(HPV)疫苗接种;提出通过对17-20岁女性代表性样本定期开展尿液HPV检测,可在接种前后监测单剂次疫苗程序的人群总体有效性,并建议将接种目标对准首次性行为年龄相近的出生队列及18岁以下补种队列。

要点

  • 单剂次HPV疫苗接种可针对首次性行为年龄相近的出生队列以尽早获得总体有效性信息。
  • 对18岁以下女孩补种单剂次可缩短接种与监测影响之间的间隔。
  • 对17-20岁女性代表性样本定期尿液HPV检测是评估疫苗总体有效性的可行方法。

核心结论

  • 基于现有关于效力、节约和接种便利的证据,部分国家可能在WHO政策决定前试点或推广单剂次HPV疫苗接种。
  • 通过接种引入前后对年轻女性HPV患病率进行定期调查,可加速获得单剂次疫苗程序的人群总体有效性证据。
  • 单剂次HPV疫苗真实世界总体有效性演示将补充正在进行的单剂次HPV疫苗效力临床试验和免疫原性研究的结果。

研究设计与样本

  • 本文为方法学讨论,提出通过观察性研究设计评估单剂次HPV疫苗程序的人群总体有效性。
  • 建议对17-20岁女性代表性样本定期进行尿液HPV检测,并指出该观察性研究将受益于人口普查和疫苗接种登记系统的建立。

主要发现

  • 单剂次HPV疫苗接种应针对一个或多个尽可能接近该人群首次性行为最常见年龄的出生队列,以提供最早的总体有效性信息。
  • 对18岁以下女孩补种单剂次HPV疫苗可最小化接种与监测年轻女性疫苗影响可能性之间的间隔。
  • 在筛查可及性低的中低收入国家,补种尤其可取,因为错过队列可能面临高宫颈癌死亡风险。
  • 尿液HPV检测与宫颈细胞检测已证明有良好一致性,为在17-20岁女性代表性样本中定期评估疫苗总体有效性提供了可行方法。

临床怎么用

  • 作者提出单剂次HPV疫苗接种应针对接近首次性行为年龄的出生队列,并可对18岁以下女孩补种以尽早监测影响。
  • 作者提出对17-20岁女性代表性样本定期采用尿液HPV检测评估疫苗总体有效性。
  • 作者提出该观察性研究可受益于人口普查和疫苗接种登记系统的建立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Based on existing evidence for efficacy, savings, and advantages in delivery, some countries may elect to pilot or roll out single-dose human papillomavirus (HPV) vaccination (instead of, or in combination with, two-dose) in advance of a WHO policy decision. Accelerated evidence of population-based effectiveness (hereafter referred to as overall effectiveness, OE) of one-dose vaccine programs could be gained through regular surveys of HPV prevalence in young women before and after vaccination introduction. In order to offer the earliest information on OE, one-dose HPV vaccination should target one or more birth cohorts as close as possible to the age when sexual activity most often starts in a given population. A catch-up one-dose vaccination program of girls up to 18 years of age who would have been too old to profit from the introduction of a routine HPV vaccination program in preadolescents would minimize the interval between vaccination and the possibility to monitor vaccination impact in young women. In addition, catch-up is especially desirable in low- and middle-income countries with little access to screening as "missed" cohorts may face high risk of cervical cancer death. HPV prevalence should be firstly monitored in age groups of women who may already be sexually active but still reluctant to admit it and to accept vaginal examination for the collection of cervical cells. Hence, HPV testing from urine samples, for which good concordance with cervical cells has been proven, offers a feasible approach to assess periodically vaccine OE in representative samples of 17-20 year-old women. This type of observational study would greatly benefit from the presence of a population census and the creation of a vaccination registry. A real-world demonstration of OE of the new schedule would complement the findings of ongoing clinical trials and immunogenicity studies on the efficacy of single-dose HPV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Franceschi S, Clifford GM, Baussano I, et al. Options for design of real-world impact studies of single-dose vaccine schedules. Vaccine. 2018. PMID: 29571973. doi:10.1016/j.vaccine.2018.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。